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ABSTRACT
Objective: To examine the risk of fracture in patients with multiple sclerosis (MS) compared with
population-based controls.
Methods: A population-based cohort study was performed in the Dutch PHARMO Record Linkage
System (1998–2008). Patients with MS (n ! 2,415) were matched by year of birth, sex, and
practice to up to 6 patients without MS (controls). We used Cox proportional hazards models to
estimate the hazard ratio (HR) of fracture inMS. Time-dependent adjustments weremade for age,
history of disease, and drug use.
Results: During follow-up, there were 59 fractures among patients with MS (2.4%) and 227 frac-
tures among controls (1.8%). Patients with MS had a 1.7-fold increased risk of osteoporotic
fracture (HR 1.73 [95% confidence interval (CI) 1.18–2.53]) and a 4-fold increased risk of hip
fracture (HR 4.08 [95% CI 2.21–7.56]). The risk of osteoporotic fracture was significantly
greater for patients with MS who had been prescribed antidepressants (HR 3.25 [95% CI 1.77–
5.97]) or hypnotics/anxiolytics (HR 3.40 [95% CI 2.06–5.63]) in the previous 6 months, com-
pared with controls.
Conclusions: Increased awareness of the risk of hip fracture is warranted in patients with MS,
especially in those who have recently been prescribed antidepressants or hypnotics/anxiolytics.
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GLOSSARY
ATC!Anatomic Therapeutic Chemical;BMD! bonemineral density;BMI! bodymass index;CI! confidence interval;GC!
glucocorticoid; HR ! hazard ratio; ICD ! International Classification of Diseases; MS ! multiple sclerosis; RLS ! Record
Linkage System.
Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the CNS, characterized by
acute focal demyelination and axonal loss. It is one of the most common causes of neurologic
disability in young adults1 and affects approximately 1.3 million people worldwide.2
Patients with MS often have multiple risk factors for fracture,3 including low bone mineral
density (BMD)4–8 and an increased risk of falling.9–11 The increased risk of falling may be
caused by poorer postural balance, impaired vision, disability, or spasticity.9,11,12 Explanations
for low BMD in MS include vitamin D deficiency,4–6,13 immobility,6,7 a low level of daily
activity,4,14 and the use of glucocorticoids (GCs).4,7,15 Furthermore, it has been recognized that
inflammatory autoimmune disease may promote local and systemic bone destruction by oste-
oclasts and inhibit bone formation by osteoblasts.16 The acute inflammation associated with
MS might therefore lead to bone loss.5
To our knowledge, there has previously been only one study that quantified the risk of
fracture in patients with MS.17 The aim of this study was to estimate the risk of fracture in
patients with MS compared with population-based controls.
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METHODS Data source. Information for this study was
retrieved from the Dutch PHARMO Record Linkage System
(RLS). The PHARMO RLS is a large, patient-centric data net-
work including multiple linked observational databases designed
for safety and outcomes research of drugs which collates patient
records in 48 geographically defined areas in the Netherlands
(covering a demographic region of 3 million inhabitants). For
this source population, we have used pharmacy dispensing data
linked to the national hospitalization registry of the Nether-
lands.18,19 Drug exposure information includes drug name, type
of prescriber, dispensing date, amount dispensed, dosage instruc-
tions, and cost. Hospitalizations in the national hospitalization
registry are coded with a discharge diagnosis, or a diagnosis for a
day care admission (e.g., to receive IV administered drugs such as
natalizumab) according to the International Classification of
Diseases (ICD-9). In case a hospitalization is due to an external
cause, such as an accident or poisoning, hospitals in the Nether-
lands are required to add a supplementary code to the code from
one of the main chapters of ICD-9, indicating the nature of the
condition (E800–E999). A previous study using PHARMO
RLS data has demonstrated a high level of data validity with
respect to the reporting of hip fractures ("89% of fractures were
confirmed).20
Study population and design. We conducted a retrospec-
tive follow-up study on patients with MS and population-based
controls. Our case population included all patients aged 18 years
or older with at least one hospitalization with a recorded diagno-
sis of MS (ICD-9-CM: 340) during the period of PHARMO
RLS data collection (January 1998–December 2008). The index
date for the patients with MS was defined as the date of the first
diagnosis of MS after enrolment in PHARMO RLS. Each pa-
tient with MS was subsequently matched by year of birth, sex,
and practice to up to 6 randomly selected controls from the
general population (i.e., patients without a recorded diagnosis of
MS in the national hospitalization registry at any time during
enrolment). Controls were given the index date of their corre-
sponding matched case.
Cases and controls were then followed from their index
date to the end of data collection, the date of transfer of the
patient out of the practice area, or the patient’s death, which-
ever came first.
Study outcomes. The records of all study participants were
inspected for the occurrence of fractures after the index date.
Fractures were classified according to ICD-9 categories 800–
829. A clinical osteoporotic fracture was defined as a fracture of
the radius/ulna, vertebrae, femur, hip, humerus, pelvis, or ribs.
In addition, the supplementary classification of external causes
was used to identify which fractures were coded with a fall
(ICD-9 categories E880–886 or E888). For any, osteoporotic
and hip fracture, we considered 2 additional endpoints: fractures
with a recorded fall and fractures without a recorded fall.
Bias and confounding. The follow-up period for each partic-
ipant was divided into 30-day intervals. The presence of risk
factors was determined by reviewing the computerized records
for any evidence of each risk factor before the start of an interval.
Potential confounders that were determined at baseline were
sex and history of fracture. For a time-dependent analysis we
considered age, a history of chronic diseases (asthma, congestive
heart failure, rheumatoid arthritis, cerebrovascular disease,21
noninfectious enteritis and colitis, renal failure, dementia, and
epilepsy), as well as a history of falling 1 year to 3 months before
the start of each 30-day interval. Any prescriptions for oral
GCs,22,23 statins, antiarrhythmics (excluding digoxin and sota-
lol), antidiabetics, antidepressants,24 antipsychotics,25 hypnotics/
anxiolytics,26 anticonvulsants,27 estrogen containing hormone
replacement therapy,28 calcium, vitamin D, bisphosphonates,
opioids, or asthma medication 6 months before the start of an
interval were also considered as potential confounders. Table e-1
on the Neurology® Web site at www.neurology.org shows ICD-9
and Anatomic Therapeutic Chemical (ATC) codes.
Statistical analysis. Cox proportional hazards models were
used to provide an estimate of the relative risk (hazard ratio
[HR]) of fracture among patients with MS, adjusted for any
potential confounders that changed the HR"1% in an age/sex-
adjusted analysis. Analyses were stratified by duration of disease
(time since first diagnosis recorded in PHARMO RLS) and drug
use in the previous 6 months. We determined the proportion of
patients with at least 1 prescription for vitamin D, calcium, or a
bisphosphonate during follow-up. All statistical analyses were
conducted using SAS® 9.1/9.2 software.
Standard protocol approvals, registrations, and patient
consents. Ethical approval for the study was obtained from the
PHARMO institute.
RESULTS The study population included 2,415 pa-
tients with a hospitalization for MS and 12,641
population-based controls. Baseline characteristics of
the participants are given in table 1. Of all patients
with MS, 72.2% were female and the mean age at
index date (first recorded diagnosis of MS in our da-
taset) was 43.6 years. Of all patients with MS, 59
experienced a fracture during follow-up. Of these, 39
were osteoporotic fractures and 20 concerned other
types of fracture, which included fractures of the face
bones (n ! 2), fractures of the hand (n ! 2), frac-
tures of tibia/fibula (n ! 6), and fractures of the
foot/ankle (n ! 10).
Table 2 reveals that patients with MS had a 4-fold
increased risk of hip fracture compared with con-
trols. The risk of osteoporotic fracture was increased
1.7-fold. Risks of any, osteoporotic, and hip fracture
were significantly increased when the fracture had
occurred in conjunction with a fall. However, for
fractures without a recorded fall, risks were not sig-
nificantly increased. Furthermore, the risk of any
fracture was increased in women with MS vs women
without MS, but not in men with MS vs men with-
out MS.
The risk of osteoporotic fracture was significantly
greater (more than 3 times increased) for patients
with MS who had been prescribed antidepressants or
hypnotics/anxiolytics in the previous 6 months,
compared with all controls (table 3). In addition, a
longer duration of disease appeared to be associated
with a greater risk of osteoporotic fracture. A com-
parison between patients with MS and controls who
both used the same type of medication yielded
slightly different HRs than the results in table 3: os-
teoporotic fracture risk among patients with MS who
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had been prescribed antidepressants compared to
“control” patients who had been prescribed antide-
pressants yielded adjusted HR 2.52 (95% confidence
interval [CI] 1.15–5.52), while prescription of hyp-
notics/anxiolytics among patients with MS revealed
an adjusted HR of 4.06 (95% CI 2.13–7.75) com-
pared to “control” patients who had been prescribed
this medication (data not shown). When we com-
pared patients with MS who had used antidepres-
sants and controls who also had used antidepressants
with nonexposed patients, we found a significant dif-
ference between exposed patients with MS and ex-
posed controls (p ! 0.006). For the use of
hypnotics/anxiolytics, the difference between pa-
tients with MS and controls was significant as well
(p # 0.001).
A small proportion of the patients with MS had
been prescribed calcium (3.1%), vitamin D (3.8%,
sometimes in combination with calcium), or a bis-
phosphonate (4.8%) at least once during follow-up.
In controls these proportions were 2.3%, 3.0%, and
2.8%, respectively.
DISCUSSION In this study, we found that patients
with MS had a 4-fold greater risk of hip fracture than
controls. Overall, we found that the risk of osteoporotic
fracture was increased 1.7-fold, and that fracture risk
was significantly greater for patients with MS who had
recently been prescribed antidepressants or hypnotics/
anxiolytics, compared with controls.
Our results are in line with those from other stud-
ies that have reported on fracture risk17 or low BMD
in patients with MS.4–8 Using data from the General
Practice Research Database (UK), we have previously
shown that patients with MS were at an increased
risk of fracture.17 In that study, patients with MS
(n ! 5,565, 5.7 years of follow-up from their first
MS diagnosis) had an almost 3-fold increased risk of
hip fracture and a risk of osteoporotic fracture that
was increased 1.4-fold, compared with controls. A
cohort study4 reported that at baseline patients with
MS had had significantly more fractures than age-
matched controls and BMD in patients with MS was
almost 1 SD lower in the spine and 1 to 1.6 SD lower
in the femoral neck. However, the authors do not
provide duration of disease. A Turkish study6 exam-
ined patients with MS (mean duration of disease 7.3
years) and found that BMD at the lumbar spine in
MS was nearly 1 SD lower than in controls. Simi-
larly, a cross-sectional study showed that BMD val-
ues were significantly lower in patients with MS
(mean disease duration 8.4 years in women and 10.4
years in men) at the lumbar spine and femoral sites,
compared with controls.8 A reduced BMD at either
the lumbar spine or the femoral neck was found5 in
80% of male patients with MS with a mean disease
duration of 17.0 years. Of these men, 43% had os-
teopenia and 37% had osteoporosis. In women with
MS, 38% had osteopenia and 44% had osteoporosis.
In this study, we found that the risk of fracture was
increased in female patients with MS, but not in
male patients with MS. This may be explained by
lower bone mass in women with MS.3
The increased risk of hip fracture that we found in
association with MS may be caused by different un-
derlying mechanisms. It is generally accepted that
MS increases the risk of falling,9–11 due to the symp-
toms of the disease including imbalance, muscle
weakness, blurred vision, and dizziness. In our study,
we found that the risk of fracture for patients with
MS was particularly elevated when considering frac-
Table 1 Baseline characteristics of patients
with MS and controls
Characteristics
MS patients
(n! 2,415)
Controls
(n! 12,641)
Female, n (%) 1,744 (72.2) 9,220 (72.9)
Age at index date, y
Mean 43.6 43.7
By category, n (%)
18–29 298 (12.3) 1,568 (12.4)
30–39 634 (26.3) 3,243 (25.7)
40–49 755 (31.3) 3,933 (31.1)
50–59 491 (20.3) 2,647 (20.9)
60" 237 (9.8) 1,250 (9.9)
Mean duration of follow-up, y 4.7 4.7
History of comorbidity, n (%)
Fracture 30 (1.2) 194 (1.5)
Asthma 2 (0.1) 33 (0.3)
Rheumatoid arthritis 5 (0.2) 17 (0.1)
Cerebrovascular incident 26 (1.1) 66 (0.5)
Epilepsy 10 (0.4) 33 (0.3)
History of drug use 1 year
before the index date, n (%)
Statins 116 (4.8) 764 (6.0)
Antiarrhythmics 5 (0.2) 38 (0.3)
Antidiabetics 59 (2.4) 416 (3.3)
Antidepressants 273 (11.3) 1,103 (8.7)
Antipsychotics 42 (1.7) 232 (1.8)
Anxiolytics/hypnotics 541 (22.4) 2,094 (16.6)
Anticonvulsants 166 (6.9) 245 (1.9)
Opioids 152 (6.3) 577 (4.6)
Oral glucocorticoids 150 (6.2) 538 (4.3)
Calcium 22 (0.9) 141 (1.1)
Vitamin D 25 (1.0) 130 (1.0)
Bisphosphonates 35 (1.4) 121 (1.0)
Abbreviation: MS!multiple sclerosis.
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tures related to a fall. A Swedish study9 found that
the odds of falling were doubled for each whole step
on the Expanded Disability Status Scale score for pa-
tients with scores between 3.5 and 6.0. Another
study11 reported that never or occasional use of a
wheelchair approximately doubled the risk of falling
compared with the use of a wheelchair all the time.
Thus, the association between disability and risk of
fracture is unclear. Intuitively, the more disabled a
patient becomes, the greater might be their risk of
falling. When a patient starts using a wheelchair,
however, their risk might actually decline. Certainly,
immobility has been linked with a reduced BMD,
probably due to increased renal calcium losses, de-
creased gastrointestinal calcium absorption, and in-
creased bone turnover.7 Other causes of low BMD in
patients with MS include the inflammatory nature of
MS,29 the use of GCs,4,7,15 and low vitamin D levels.6
These are discussed next.
MS is an inflammatory autoimmune disorder and
it has been shown that inflammatory autoimmune
disease often leads to bone loss.16 Among the sup-
posed mechanisms of bone loss are the increased de-
struction by osteoclasts, both locally and
systemically, as well as the inhibition of bone forma-
tion by osteoblasts.
GC-induced osteoporosis can also be explained
by systemic or direct effects on bone cells.30 It has
been demonstrated that patients who receive several
courses of high-dose GCs (daily dose "15 mg and
cumulative exposure "1 g in prednisolone equiva-
lents) have a substantially increased risk of fracture.23
Patients with MS who experience a relapse are often
prescribed a short course of methylprednisolone,
either orally or IV, with a dosage that corresponds to
1.5–3.3 g prednisone equivalents. However, in our
study, the number of osteoporotic fractures among
recent GC users was too low to assess the role of GCs
on fracture risk and information on the use of IV
GCs was not available. Nevertheless, it is possible
that the use of GCs might contribute to the increased
risk of osteoporotic fracture observed.
It has been shown that vitamin D deficiency is
common in patients with MS.4–6 Vitamin D defi-
ciency has been associated with low BMD6 and, in
addition, low vitamin D levels may modulate the
clinical course of MS.31,32 In our study, we found that
only a small percentage of patients with MS had been
prescribed vitamin D and we were unable to capture
other sources of vitamin D (e.g., through over the
counter use, diet, or sunlight exposure). Therefore
we cannot comment on its association with fracture
risk. Nevertheless, in case vitamin D proves to have a
positive effect on the course of disease and increased
BMD, treatment may provide beneficial effects on 2
clinically relevant aspects of MS.
In this study, among recent users of hypnotics/
anxiolytics, we found significantly more osteoporotic
fractures associated with MS, a finding that corrobo-
rates reports from elsewhere.33 In addition, we found
that in patients prescribed antidepressants, osteopo-
rotic fracture risk was increased for patients with MS,
a finding also reported elsewhere.24 One of the possi-
ble mechanisms by which antidepressant use may
contribute to fracture risk is the effect that antide-
pressants could have on the microarchitecture of
bone.34 Also, the use of antidepressants has been as-
sociated with an increased risk of falling35 and de-
pression itself might also increase fracture risk.36
Strengths of our study include its reasonable sam-
ple size and the duration of follow-up. This is one of
the first studies to estimate the risk of fracture in
Table 2 Risk of fracture in patients with MS (n! 2,415) compared with
controls (n! 12,641), by type of fracture
Fracture,
n (%)
Age-/sex-adjusted
HR (95%CI)
Fully adjusted
HR (95%CI)
NoMS 227 (1.8) 1 1
MS
Any fracture 59 (2.4) 1.41 (1.06–1.88) 1.33 (0.99–1.78)a
With a recorded fall 39 (1.6) 2.28 (1.57–3.31) 2.06 (1.40–3.02)
Without a recorded fall 20 (0.8) 0.80 (0.50–1.29) 0.79 (0.49–1.28)
Osteoporotic 39 (1.6) 2.04 (1.41–2.94) 1.73 (1.18–2.53)b
With a recorded fall 29 (1.2) 2.88 (1.84–4.50) 2.32 (1.46–3.71)
Without a recorded fall 10 (0.4) 1.10 (0.56–2.18) 1.01 (0.50–2.03)
Femur (excluding hip) 1 (0.0) —f
Hip 20 (0.8) 4.73 (2.62–8.53) 4.08 (2.21–7.56)c
With a recorded fall 16 (0.7) 5.25 (2.67–10.31) 4.61 (2.28–9.32)
Without a recorded fall 4 (0.2) 3.40 (0.99–11.66) 2.76 (0.77–9.91)
Vertebral 6 (0.2) 1.48 (0.60–3.65) 1.29 (0.52–3.22)d
Humerus 6 (0.2) 2.10 (0.81–5.41) 2.10 (0.81–5.41)e
Ribs 5 (0.2) 3.79 (1.20–11.96) 3.79 (1.20–11.96)e
Pelvis 1 (0.0) —f
Radius/ulna 0
By sex
Maleg 17 (2.5) 0.91 (0.55–1.53) 0.88 (0.52–1.48)
Femaleh 42 (2.4) 1.78 (1.25–2.52) 1.67 (1.17–2.38)
Abbreviations: CI! confidence interval; HR! hazard ratio; MS!multiple sclerosis.
a Adjusted for age, sex, the use of antidepressants, anticonvulsants, and bisphosphonates
in the previous 6 months.
b Adjusted for age, sex, the use of statins, antidepressants, hypnotics/anxiolytics, anticon-
vulsants, bisphosphonates, opioids in the previous 6 months.
c Adjusted for age, sex, the use of antidepressants, anticonvulsants, opioids in the previous
6 months.
d Adjusted for age, sex, the use of hypnotics/anxiolytics in the previous 6 months.
e Adjusted for age, sex.
f Subgroup too small to estimate HR.
g Male patients with MS vs male controls.
h Female patients with MS vs female controls.
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patients with MS compared with healthy controls us-
ing a large population-based cohort. Moreover, we
had detailed longitudinal information on drug pre-
scribing, which enabled us to stratify by exposure to
medication.
Our study has several limitations. Data on smok-
ing and body mass index (BMI) were not available.
In our study, the absence of data on smoking and
BMI may have led to an overestimation of the associ-
ation between MS and fracture risk.37,38 Information
on the degree of disability in patients with MS was
lacking too, as well as information on the course of
each patient’s disease and data on medication that
has been administered in hospitals. Because patients
with MS in our study were included based on a hos-
pital registration, there may have been a selection
bias toward patients with more severe MS. There-
fore, there may have been patients with MS in our
cohort who had longstanding MS before their start of
follow-up, although the mean length of their disease
(at first recorded ICD code) has probably decreased
during the period of data collection. Over the last
decade, the number of day care admissions for Dutch
patients with MS has increased approximately 4-fold,
from 2.6/10,000 person-years in 1998, to up to 9.4/
10,000 person-years in 2008,39 probably because of
the availability of new treatment options such as na-
talizumab. A small proportion of our control patients
may have had MS, because we could only identify
patients with MS from the registry of inpatient and
day care admissions. This may have slightly de-
creased the HR toward the null. Since PHARMO
RLS only comprises information on inpatient diag-
noses, there may have been an underregistration of
fractures of extremities. Not every patient with such
a fracture may be hospitalized, but treated as an out-
patient instead. This may have led to a nondifferen-
tial misclassification and thus an underestimation of
a true association between MS and these fracture
types. Furthermore, we cannot be certain whether
the increased risk of fracture that we found with ex-
posure to antidepressants and hypnotics/anxiolytics
was associated with use of the medication or worsen-
ing of MS. Although the control population in our
study (which was pharmacy–based) may have
slightly differed from the controls in our UK study
(which were general practitioner–based), this has
probably not substantially influenced our pivotal re-
sults, because they were similar. The ICD and ATC
codes that were used for the potential confounding
variables have not been validated.
The identification of patients with MS using one
recorded ICD code indicating MS in PHARMO
RLS has not been validated. We have however ana-
lyzed data from the United Kingdom and Denmark.
The study population from the United Kingdom has
been described elsewhere.17 Work on the Danish
study population has been accepted for publication
but not published yet. In brief, we identified all pa-
tients from the nationwide Danish MS Registry
(from 1949 onwards)40 and linked their data to the
national hospitalization registry using a unique per-
sonal identifier. The linked dataset comprised
13,841 patients with MS. In the United Kingdom,
80.7% of all MS diagnoses that were recorded in the
national hospital registry were also recorded in the
UK General Practice Research Database. In Den-
mark, 99.5% of all MS diagnoses in the national hos-
pital registry were also recorded in the national MS
Registry. The chance of a false-negative was 31% in
the UK data (probable patients with MS from the
GPRD study who had no diagnosis in the national
Table 3 Risk of osteoporotic fracture in patients with MS (n! 2,415)
compared with controls (n! 12,641), by history of drug use and
duration of disease
Fracture,
n (%)
Age-/sex-adjusted
HR (95%CI)
Fully adjusted
HR (95%CI)a
NoMS 105 (0.8) 1 1
MS
Osteoporotic fracture 39 (1.6) 2.04 (1.41–2.94) 1.73 (1.18–2.53)
Duration of disease, yc
<1 5 (12.8) 1.55 (0.63–3.85) 1.35 (0.54–3.35)
1–5 21 (53.8) 2.09 (1.30–3.34) 1.76 (1.09–2.85)
>5 13 (33.3) 2.22 (1.23–3.99) 1.87 (1.03–3.41)
History of drug use in
previous 6months
Oral glucocorticoids
Yes 1 (2.6) 1.06 (0.15–7.16) 0.70 (0.10–5.09)
No 38 (97.4) 2.09 (1.44–3.03) 1.79 (1.22–2.63)
Antidepressants
Yes 13 (33.3) 4.18 (2.35–7.44)b 3.25 (1.77–5.97)b
No 26 (66.7) 1.62 (1.06–2.49) 1.47 (0.95–2.28)
Hypnotics/anxiolytics
Yes 21 (53.8) 4.39 (2.75–7.03)b 3.40 (2.06–5.63)b
No 18 (46.2) 1.25 (0.76–2.07) 1.16 (0.70–1.93)
Anticonvulsants
Yes 7 (17.9) 3.22 (1.49–6.92) 2.49 (1.14–5.45)
No 32 (82.1) 1.89 (1.27–2.80) 1.69 (1.13–2.52)
Opioids
Yes 7 (17.9) 5.14 (2.39–11.07)b 3.29 (1.45–7.46)
No 32 (82.1) 1.80 (1.21–2.67) 1.60 (1.07–2.39)
Abbreviations: CI! confidence interval; HR! hazard ratio; MS!multiple sclerosis.
a Adjusted for age, sex, the use of statins, antidepressants, hypnotics/anxiolytics, anticon-
vulsants, bisphosphonates, opioids in the previous 6 months.
b Statistically significant difference (p # 0.05) between patients with MS with a history of
medication use and patients with MS unexposed to the same class of medication, based on
Wald test.
c From the first recorded International Classification of Diseases code indicating MS.
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hospital registry) and 4.1% in Denmark (patients
who were registered with MS in the MS Registry, but
had no diagnosis in the national hospital registry).
For a false-positive, chances were 8.5% in the UK
data (patients who had a recorded MS diagnosis in
the hospital registry, but were not probable patients
in GPRD) and 2.3% in Denmark (recorded MS di-
agnosis in the hospital registry, but not in the MS
Registry).
Overall, we found that patients with MS had a sub-
stantially increased risk of hip fracture and that the risk
of osteoporotic fracture was greater for patients with
MS who had recently been prescribed hypnotics/anx-
iolytics or antidepressants. Fracture risk assessment may
be indicated in patients with MS.
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Do You Know What is Happening to Neurology on
Capitol Hill?
Congress is making decisions that affect neurologic research funding and the way neurology is practiced
in the United States. OnlyCapitol Hill Report on AAN.com takes you behindWashington’s closed doors
and shines a light on how your federal legislators are working for—or against—your interests. Read
Capitol Hill Report on AAN.com the second and fourthWednesday of each month. Stay informed. Your
work depends on it.
AAN Publishes New Guidelines on Migraine
Prevention
Research shows that many treatments can help prevent migraine in certain people, yet few people
with migraine who are candidates for these preventive treatments actually use them, according to
two new guidelines issued by the American Academy of Neurology. The guidelines were published
in the April 24, 2012, issue of Neurology!.
To read the guidelines and access PDF summaries for clinicians and patients, a slide presentation,
and a clinical example, visit www.aan.com/go/practice/guidelines. For more information, contact Julie
Cox at jcox@aan.com or (612) 928-6069.
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